*sponsored by Huge Alerts
Good day, 360!
👉Quick heads up we’ll be welcoming back an awesome volume trader & technical analyst to the Market Master’s RoomTODAY at 11AM EST – but join us ALL DAY! (complimentary)
FOCUS LIST🔎
BURU – Up over 50% in the pre-market after securing strategic $65 million funding program to accelerate commercialization, including $15 Million PIPE investment & $50M equity line of credit
VIRI – Up over 30% in pre after announcing merger with Wex Pharmaceuticals, Inc. to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)
BPTH – Up over 48% in pre after announcing initiation of development of therapeutic program for treatment of obesity
*sponsored by Huge Alerts
And it could be gearing UP for a MASSIVE rally!
*By clicking the link, you’ll be opted in to receive Huge Alerts upcoming report and more!
HOTLIST🔥
BURU – Up over 50% in the pre-market after securing strategic $65 million funding program to accelerate commercialization, including $15 Million PIPE investment & $50M equity line of credit
Nuburu Inc. (BURU) engages in high-power, high-brightness blue laser technology business for welding and 3D printing industries worldwide.
In the after-hours yesterday, the company announced a comprehensive funding program of approximately $65 million, including $15 million of direct investment and $50 million equity line of credit.
The agreement is with Liqueous LP, a Delaware limited partnership.
The stock traded up over 50% in the pre-market in reaction to the news.
The $0.65 area acted as resistance in the after-hours and now becomes a potential support level.
Above it, targets to the upside are $0.72 and then the pre-market high at $0.85. Beyond that, $0.90, $1.05, $1.25 and $1.50 come into play.
Below $0.65, targets to the downside are $0.55, $0.50 and then a gap fill at $0.4471.
VIRI – Up over 30% in pre after announcing merger with Wex Pharmaceuticals, Inc. to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”) yesterday
Virios Therapeutics Inc. (VIRI) is a development-stage biotechnology company that focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response.
In the pre-market yesterday, the company announced that Virios has entered into a definitive share exchange agreement with Sealbond Limited, an indirect parent of Wex, pursuant to which the companies will combine in an all-stock transaction.
Highlights of the deal include:
Strategic financing by an affiliate of CK Life Sciences Int’l., (Holdings) Inc., results in working capital of approximately $23 million to fund operations and advance Phase 2b Halneuron® development into 4Q25
Expanded pipeline includes a potential first-in-class non-opioid, NaV1.7 inhibition pain treatment, Halneuron®, currently in Phase 2b development for chemotherapy-induced neuropathic pain, with an expected interim readout 2H25
Near-term catalyst with top-line results from the IMC-2 Long-COVID Phase 2a study expected in early 4Q24
Existing VIRI stockholders to be granted a contingent value right (“CVR”) tied to potential milestone payments associated with any future corporate partnering transactions for IMC-1 and IMC-2
Company announces 25-for-1 reverse stock split of its common stock to be effective on October 9, 2024 to enable business combination and Nasdaq listing compliance
Despite an initially negative reaction to the deal yesterday, with VIRI down over 18%, the stock has paired losses and is gapping higher this morning, up over 30% in the pre-market.
The $0.18 area has acted as support in the pre-market and will be an important level to watch.
Above it, targets to the upside are $0.20, $0.22, $0.24 and then the pre-market high at $0.26. Beyond that $0.28, $0.30, $0.33, $0.38 and $0.43 come into play.
Below $0.18, targets to the downside are $0.16 and then a gap fill at $0.1379.
BPTH – Up over 48% in pre after announcing initiation of development of therapeutic program for treatment of obesity
Bio-Path Holdings Inc. (BPTH) operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States.
In the pre-market this morning, the company announced the initiation of a therapeutic program to develop BP1001-A for the treatment of obesity and related metabolic diseases. This program marks the first application of DNAbilize technology for development of a non-cancer application, which highlights the broad therapeutic potential of this technology.
The stock traded up over 48% in the pre-market in reaction to the news.
The first target for bulls is the pre-market high at $1.52. Beyond that, $1.60, $1.87, $2 come into play.
Below $1.52, targets to the downside are $1.40, $1.30, $1.20, $1.10, $1 and then a gap fill at $0.8513.
MARKET NEWS 📰
P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of our latest HOT STOCK ideas!
Questions or concerns about our products? Email [email protected] © Copyright 2022, RagingBull
DISCLAIMER: To more fully understand any Ragingbull.com, LLC (“RagingBull”) subscription, website, application or other service (“Services”), please review our full disclaimer located at https://ragingbull.com/disclaimer
FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision.
RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers’ trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment.
RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers.
RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled.
*Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals.
WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.
